RK Pharma

Executive Summary

RK Pharma Inc. is a privately held US-based generic pharmaceutical company founded in 2018, headquartered in San Diego. The company specializes in the development, manufacturing, and commercialization of high-quality, affordable generic drugs, with a focus on products featuring formulation challenges and first-to-market generic opportunities. By targeting complex generics and niche therapeutic segments, RK Pharma aims to differentiate itself in the competitive generic market, which is driven by patent expirations and demand for cost-effective alternatives. Operating with an integrated model spanning development, regulatory affairs, and manufacturing, RK Pharma is well-positioned to capitalize on upcoming drug patent cliffs. The company's emphasis on first-to-market generics could yield significant revenue opportunities and potential partnerships with larger pharmaceutical firms. While the generic drug market is characterized by pricing pressures and regulatory hurdles, RK Pharma's specialized strategy and lean private structure may enable agility and efficient capital allocation, supporting sustainable growth in the near to medium term.

Upcoming Catalysts (preview)

• Q4 2026ANDA Filing for a First-to-Market Complex Generic50% success
• Q2 2027Strategic Partnership or Licensing Deal for Distribution40% success
• Q3 2026Series B/C Funding Round to Expand Manufacturing Capacity70% success